PLX Valuation

Protalix Biotherapeutics Inc

Add to Watchlist

Advanced Chart

1.580

+0.01(0.637%)1D

Overview
Forecast
Valuation
Earnings

PLX Relative Valuation

PLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PLX is overvalued; if below, it's undervalued.

Historical Valuation

Protalix Biotherapeutics Inc (PLX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.57 is considered Undervalued compared with the five-year average of 1.38. The fair price of Protalix Biotherapeutics Inc (PLX) is between 5.48 to 7.33 according to relative valuation methord. Compared to the current price of 1.58 USD , Protalix Biotherapeutics Inc is Undervalued By 71.14%.

Relative Value

Fair Zone

5.48-7.33

Current Price：1.58

71.14%

Undervalued

6.68

Trailing

Forward

0.00

EV/EBITDA

Protalix Biotherapeutics Inc. (PLX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.37. The thresholds are as follows: Strongly Undervalued below -1.31, Undervalued between -1.31 and -0.47, Fairly Valued between 1.21 and -0.47, Overvalued between 1.21 and 2.04, and Strongly Overvalued above 2.04. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

3.34

EV/EBIT

Protalix Biotherapeutics Inc. (PLX) has a current EV/EBIT of 3.34. The 5-year average EV/EBIT is 4.83. The thresholds are as follows: Strongly Undervalued below -20.95, Undervalued between -20.95 and -8.06, Fairly Valued between 17.72 and -8.06, Overvalued between 17.72 and 30.61, and Strongly Overvalued above 30.61. The current Forward EV/EBIT of 3.34 falls within the Historic Trend Line -Fairly Valued range.

1.57

Protalix Biotherapeutics Inc. (PLX) has a current PS of 1.57. The 5-year average PS is 2.01. The thresholds are as follows: Strongly Undervalued below -0.30, Undervalued between -0.30 and 0.86, Fairly Valued between 3.16 and 0.86, Overvalued between 3.16 and 4.32, and Strongly Overvalued above 4.32. The current Forward PS of 1.57 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Protalix Biotherapeutics Inc. (PLX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.44. The thresholds are as follows: Strongly Undervalued below -1.58, Undervalued between -1.58 and -0.57, Fairly Valued between 1.46 and -0.57, Overvalued between 1.46 and 2.47, and Strongly Overvalued above 2.47. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Protalix Biotherapeutics Inc. (PLX) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.11. The thresholds are as follows: Strongly Undervalued below -3.85, Undervalued between -3.85 and -1.37, Fairly Valued between 3.59 and -1.37, Overvalued between 3.59 and 6.08, and Strongly Overvalued above 6.08. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Protalix Biotherapeutics Inc (PLX) has a current Price-to-Book (P/B) ratio of 2.51. Compared to its 3-year average P/B ratio of 13.29 , the current P/B ratio is approximately -81.12% higher. Relative to its 5-year average P/B ratio of 19.60, the current P/B ratio is about -87.20% higher. Protalix Biotherapeutics Inc (PLX) has a Forward Free Cash Flow (FCF) yield of approximately -2.82%. Compared to its 3-year average FCF yield of -10.80%, the current FCF yield is approximately -73.87% lower. Relative to its 5-year average FCF yield of -15.70% , the current FCF yield is about -82.02% lower.

2.51

P/B

Median3y

13.29

Median5y

19.60

-2.82

FCF Yield

Median3y

-10.80

Median5y

-15.70

Competitors Valuation Multiple

The average P/S ratio for PLX's competitors is 20.71, providing a benchmark for relative valuation. Protalix Biotherapeutics Inc Corp (PLX) exhibits a P/S ratio of 1.57, which is -92.41% above the industry average. Given its robust revenue growth of -98.38%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PLX.A

Protalix Biotherapeutics Inc

Avalo Therapeutics Inc

Loss

123.24M

TARA.O

Protara Therapeutics Inc

Connect Biopharma Holdings Ltd

20.19

96.40M

CRBP.O

Corbus Pharmaceuticals Holdings Inc

100.70

118.88M

Performance Decomposition

Market capitalization of PLX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of PLX in the past 1 year is driven by Unknown.